In a year marked by significant advancements, the final episode of 2025 from the GEN team highlighted pivotal stories that shaped the pharmaceutical landscape. The discussion centered on the growing role of artificial intelligence in drug discovery, a trend that promises to streamline processes and enhance efficiency in bringing new therapies to market. Additionally, the emotional narrative surrounding Baby KJ’s successful treatment underscored the potential of cell and gene therapies, juxtaposed with the challenges faced by Sarepta’s DMD treatment, Elevidys, which experienced a tumultuous year amid safety concerns.
Contextually, these developments reflect broader trends in the industry, including the increasing investment in biotech research across Africa, which, despite facing challenges, is poised for growth. The recent NIH budget cuts have raised concerns about funding for critical research institutions, potentially impacting innovation and development. As the industry navigates these complexities, the implications for regulatory frameworks and market dynamics will be significant, necessitating vigilance from professionals in regulatory, QA/QC, and sourcing sectors.
Use the database as your supply chain compass →
